Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Deals

Novo Nordisk Acquires Alkermes’ Irish Production Site for $92.5 Million to Boost GLP-1 Output

Fineline Cube Dec 18, 2023

Novo Nordisk (CPH: NOVO-B), a Danish pharmaceutical giant, has reached an agreement to acquire a...

Company Deals

Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round

Fineline Cube Dec 18, 2023

Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence...

Company Drug

Bio-Thera Solutions Gets NMPA Green Light for PD-1 Inhibitor BAT1308 in Endometrial Cancer

Fineline Cube Dec 18, 2023

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Deals

Mingyi Zhizao Secures $14 Million to Scale Gene Sequencing Platform and Production

Fineline Cube Dec 18, 2023

Shenzhen Mingyi Zhizao Technology Co., Ltd, a Chinese company specializing in the gene sequencing industry,...

Company

Shanghai Pharmaceuticals Hit with Anti-Monopoly Fine by Shanghai Market Supervision Bureau

Fineline Cube Dec 18, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company based in China,...

Company Deals

Youcare Pharmaceutical Partners with Sinopharm Heilongjiang to Broaden Market Presence

Fineline Cube Dec 18, 2023

Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with...

Company Drug

Sanofi’s Rezurock Secures Marketing Approval in China for Chronic Graft-vs-Host Disease

Fineline Cube Dec 18, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that its drug Rezurock (belumosudil), the world’s...

Company Drug

InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study

Fineline Cube Dec 18, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and...

Company Drug

MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma

Fineline Cube Dec 15, 2023

The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...

Company Deals

Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response

Fineline Cube Dec 15, 2023

German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health...

Company Drug

3D Medicines Initiates Phase III Trial for Envafolimab in NSCLC Patient

Fineline Cube Dec 15, 2023

3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the enrollment of the first...

Company Deals

BMS Partners with Terray Therapeutics for AI-Driven Drug Discovery

Fineline Cube Dec 15, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with U.S.-based Terray Therapeutics...

Company Deals

Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics

Fineline Cube Dec 15, 2023

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have...

Company Deals

VectorBuilder Partners with Sino Biological to Boost Global Biological Reagents Market

Fineline Cube Dec 15, 2023

VectorBuilder, a genetic engineering specialist based in Guangzhou and nurtured by the state-owned Guangzhou Industrial...

Company Deals

CATUG Biotechnology Partners with Carcell Biopharma to Advance Nucleic Acid Drug Development

Fineline Cube Dec 15, 2023

CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with...

Company Drug

Sino Biopharmaceutical Submits Market Approval Application for Recombinant Coagulation Factor VIIa

Fineline Cube Dec 15, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Lepu Biotechnology’s Pancreatic Cancer Drug Earns Orphan Drug Status from FDA

Fineline Cube Dec 15, 2023

Lepu Biotechnology Co., Ltd (HKG: 2157), a Chinese pharmaceutical company, has announced that it has...

Company Deals

AbelZeta Pharma Expands Janssen Partnership to Include Commercial Rights in China

Fineline Cube Dec 15, 2023

AbelZeta Pharma Inc., a Sino-US biotechnology company with operations in Rockville, Maryland, and Shanghai, China,...

Company Drug

AbbVie and Genmab’s Epcoritamab Shows Promising Results in Follicular Lymphoma Study

Fineline Cube Dec 14, 2023

AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have presented Phase I/II clinical data for their...

Company Drug

Amgen’s Tarlatamab Receives FDA Priority Review for Advanced Small Cell Lung Cancer Treatment

Fineline Cube Dec 14, 2023

The US Food and Drug Administration (FDA) has granted priority review status to Amgen (NASDAQ:...

Posts pagination

1 … 365 366 367 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.